Bioanalysis Zone

Hybrid assays: the next big thing?


In the near-term, the wide-spread use of hybrid assays appears to be ‘the next big thing’ in bioanalysis as evidenced by its inclusion in recent professional publications (Table 1) and discussions at scientific meetings. Consequently, the US FDA has been prompted to issue guidance/specifications/expectations for hybrid assays; however, regulatory experience with these modalities has been extremely scarce to date.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment